Abstract
Objective
To examine the efficacy of venlafaxine, which is used as an antidepressant, in the treatment of stress urinary incontinence.
Materials and methods
The study was designed as a placebo-controlled, double-blind and randomized clinical study. Patients in Group 1 (n = 20) were administered 75 mg venlafaxine, those in Group 2 (n = 20) were administered placebo for 12 weeks. All the cases were evaluated in terms of weekly incontinence episode frequency (IEF), change in void interval (VI), the Incontinence Quality of Life (I-QOL) in weeks 0, 4, 8 and 12. Additionally, PGI-S was assessed at baseline and was followed by PGI-I evaluations in weeks 4, 8 and 12.
Results
Evaluations in weeks 0, 4, 8 and 12 did not show any significant difference in IEF, VI, IQOL and PGI-I values of placebo group (p > 0.05). However, in the patients who were administered venlafaxine declines in IEF and PGI-I values as well as the elevations in VI and IQOL scores showed significant changes parallel to the increasing follow-up period (p < 0.05). Nausea was observed in 40% of cases in venlafaxine group, and 15% of those in placebo group (p < 0.05).
Conclusion
It was seen in our study that efficacy of venlafaxine started early and the clinical efficacy associated with the use of the drug continued in the following months. Venlafaxine should be considered a clinically efficient alternative drug in the treatment of SUI.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Mariappan P, Alhasso A, Ballantyne Z, Grant A, N’Dow J (2007) Duloxetine, a serotonin and noradrenaline reuptake inhibitor (SNRI) for the treatment of stress urinary incontinence: a systematic review. Eur Urol 51:67–74. doi:10.1016/j.eururo.2006.08.041
Nitti VW (2004) Duloxetine: a new pharmacologic therapy for stress urinary incontinence. Rev Urol 6:48–55
Mariappan P, Ballantyne Z, N’Dow JM, Alhasso AA (2005) Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults. Cochrane Database Syst Rev 3:4742
Norton PA, Zinner NR, Yalcin I, Bump RC (2002) Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol 187:40–48. doi:10.1067/mob.2002.124840
Bae JH, Moon DG, Lee JG (2001) The effects of a selective noradrenaline reuptake inhibitor on the urethra: an in vitro and in vivo study. BJU Int 88:771–775. doi:10.1046/j.1464-4096.2001.02389.x
Wagner TH, Patrick DL, Bavendam TG, Martin ML, Buesching DP (1996) Quality of life of persons with urinary incontinence: development of a new measure. Urology 47:67–71. doi:10.1016/S0090-4295(99)80384-7
Patrick DL, Martin ML, Bushnell DM, Yalcin I, Wagner TH, Buesching DP (1999) Quality of life of women with urinary incontinence: further development of the incontinence quality of life instrument (I-QOL). Urology 53:71–76. doi:10.1016/S0090-4295(98)00454-3
Donovan JL, Badia X, Corcos J (2002) Symptom and quality of life assessment. In: Abrams P, Cardozo L, Khoury S, Wein A (eds) Incontinence, 2nd edn. Health Publication, Plymouth, pp 267–316
Yalcin I, Bump RC (2003) Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol 189:98–101. doi:10.1067/mob.2003.379
Votolato NA, Stern S, Caputo RM (2000) Serotonergic antidepressants and urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 11:386–388. doi:10.1007/s001920070009
Inghilleri M, Conte A, Frasca V, Bettolo CM, Iacovelli E, Aragona M et al (2005) Venlafaxine and bladder function. Clin Neuropharmacol 28:270–273. doi:10.1097/01.wnf.0000191353.40812.b4
Polimeni G, Salvo F, Cutroneo P, Nati G, Russo A, Giustini ES et al (2005) Venlafaxine-induced urinary incontinence resolved after switching to sertraline. Clin Neuropharmacol 28:247–248. doi:10.1097/01.wnf.0000188205.25750.2d
Hansen LK (2004) Venlafaxine-induced increase in urinary frequency in 3 women. J Clin Psychiatry 65:877–878
Lopez-Figueroa AL, Norton CS, Lopez-Figueroa MO, Armellini-Dodel D, Burke S, Akil H et al (2004) Serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia. Biol Psychiatry 55:225–233. doi:10.1016/j.biopsych.2003.09.017
Brody AL, Saxena S, Stoessel P, Gillies LA, Fairbanks LA, Alborzian S et al (2001) Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings. Arch Gen Psychiatry 58:631–640. doi:10.1001/archpsyc.58.7.631
Pitsikas N (2000) Duloxetine Eli Lilly & Co. Curr Opin Investig Drugs 1:116–121
Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG (2001) Comparative efficacy of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25:871–880. doi:10.1016/S0893-133X(01)00298-6
Tran PV, Bymaster FP, McNamara RK, Potter WZ (2003) Dual monoamine odulation for improved treatment of major depressive disorder. J Clin Psychopharmacol 23:78–86. doi:10.1097/00004714-200302000-00011
Katofiasc MA, Nissen J, Audia JE, Thor KB (2002) Comparison of the effects of serotonin selective, norepinephrine selective, and dual serotonin and norepinephrine reuptake inhibitors on lower urinary tract function in cats. Life Sci 2(71):1227–1236. doi:10.1016/S0024-3205(02)01848-9
Conflict of interest statement
There is no any conflict of interest in this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Erdinc, A., Gurates, B., Celik, H. et al. The efficacy of venlafaxine in the treatment of women with stress urinary incontinence. Arch Gynecol Obstet 279, 343–348 (2009). https://doi.org/10.1007/s00404-008-0729-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-008-0729-x